Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V 3rd, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA.

J Subst Abuse Treat. 2016 Sep;68:62-7. doi: 10.1016/j.jsat.2016.06.002. Epub 2016 Jun 6.

PMID:
27431048
2.

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT.

Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review.

PMID:
26956246
3.

Hepatitis infection in the treatment of opioid dependence and abuse.

Kresina TF, Sylvestre D, Seeff L, Litwin AH, Hoffman K, Lubran R, Clark HW.

Subst Abuse. 2008 Apr 28;1:15-61. eCollection 2008 Apr 28. Review.

4.

Low-dose prazosin alone and in combination with propranolol or naltrexone: effects on ethanol and sucrose seeking and self-administration in the P rat.

Verplaetse TL, Czachowski CL.

Psychopharmacology (Berl). 2015 Aug;232(15):2647-57. doi: 10.1007/s00213-015-3896-z. Epub 2015 Mar 7.

5.

BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.

Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L.

Br J Pharmacol. 2015 Jan;172(2):668-80. doi: 10.1111/bph.12796. Epub 2014 Nov 5.

6.

Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.

Ciccocioppo R, Stopponi S, Economidou D, Kuriyama M, Kinoshita H, Heilig M, Roberto M, Weiss F, Teshima K.

Neuropsychopharmacology. 2014 Oct;39(11):2601-10. doi: 10.1038/npp.2014.113. Epub 2014 Jun 27.

7.

MT-7716, a novel selective nonpeptidergic NOP receptor agonist, effectively blocks ethanol-induced increase in GABAergic transmission in the rat central amygdala.

Kallupi M, Oleata CS, Luu G, Teshima K, Ciccocioppo R, Roberto M.

Front Integr Neurosci. 2014 Feb 18;8:18. doi: 10.3389/fnint.2014.00018. eCollection 2014 Feb 18.

8.

Scheduled access alcohol drinking by alcohol-preferring (P) and high-alcohol-drinking (HAD) rats: modeling adolescent and adult binge-like drinking.

Bell RL, Rodd ZA, Engleman EA, Toalston JE, McBride WJ.

Alcohol. 2014 May;48(3):225-34. doi: 10.1016/j.alcohol.2013.10.004. Epub 2013 Oct 31. Review.

9.

The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R.

Pharmacol Ther. 2014 Mar;141(3):283-99. doi: 10.1016/j.pharmthera.2013.10.011. Epub 2013 Nov 1. Review. Erratum in: Pharmacol Ther. 2014 Sep;143(3):351.

10.

Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.

Eastwood EC, Phillips TJ.

Genes Brain Behav. 2014 Feb;13(2):226-35. doi: 10.1111/gbb.12100. Epub 2013 Nov 18.

11.

Translational approach to develop novel medications on alcohol addiction: focus on neuropeptides.

Ubaldi M, Bifone A, Ciccocioppo R.

Curr Opin Neurobiol. 2013 Aug;23(4):684-91. doi: 10.1016/j.conb.2013.04.009. Epub 2013 May 3. Review.

12.

Retrodialysis of N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular dopamine and locomotor activity.

Vazquez-DeRose J, Stauber G, Khroyan TV, Xie XS, Zaveri NT, Toll L.

Eur J Pharmacol. 2013 Jan 15;699(1-3):200-6. doi: 10.1016/j.ejphar.2012.11.050. Epub 2012 Dec 5.

13.

Genetically selected alcohol preferring rats to model human alcoholism.

Ciccocioppo R.

Curr Top Behav Neurosci. 2013;13:251-69. doi: 10.1007/7854_2012_199.

14.

Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.

Lohith TG, Zoghbi SS, Morse CL, Araneta MF, Barth VN, Goebl NA, Tauscher JT, Pike VW, Innis RB, Fujita M.

J Nucl Med. 2012 Mar;53(3):385-92. doi: 10.2967/jnumed.111.097162. Epub 2012 Feb 6.

15.

Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Mannelli P, Peindl KS, Lee T, Bhatia KS, Wu LT.

Curr Drug Abuse Rev. 2012 Mar;5(1):52-63. Review.

16.

Neuropeptide modulation of central amygdala neuroplasticity is a key mediator of alcohol dependence.

Gilpin NW, Roberto M.

Neurosci Biobehav Rev. 2012 Feb;36(2):873-88. doi: 10.1016/j.neubiorev.2011.11.002. Epub 2011 Nov 11. Review.

17.

Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM.

J Med Chem. 2011 Oct 13;54(19):6531-7. doi: 10.1021/jm2003238. Epub 2011 Sep 7.

19.
20.

Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, Zaveri NT.

J Pharmacol Exp Ther. 2009 Dec;331(3):954-64. doi: 10.1124/jpet.109.157446. Epub 2009 Sep 22.

Supplemental Content

Support Center